- Home
- ASBP
as of 09-28-2026 2:17pm EST
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | ESTERO |
| Market Cap: | 12.4M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 33.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.49 | EPS Growth: | -762.11 |
| 52 Week Low/High: | $0.05 - $9.50 | Next Earning Date: | 04-08-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -1.11 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Compare ASBP vs Leading Stocks
See how ASBP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ASBP Aspire Biopharma Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.